Five-Year Outcomes of Patients (Pts) with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Treated with Brexucabtagene Autoleucel (Brexu-cel) in ZUMA-2 Cohorts 1 and 2
Year: 2024
Type: conference-abstract
Source: Blood
Authors: Michael Wang, Andre Goy, Javier Munoz, Frederick L. Locke, Caron A. Jacobson, Brian T. Hill, John Timmerman, Ian W. Flinn, David B. Miklos, John M. Pagel, Marie José Kersten, Edouard Forcade, Max S. Topp, Roch Houot, Amer Beitinjaneh, Dan Zheng, Mengru Chang, Rhine Shen, Wangshu Zhang, Rita Damico Khalid, Ioana Kloos, Patrick M. Reagan
Institutions: The University of Texas MD Anderson Cancer Center, Mayo Clinic Hospital, Banner MD Anderson Cancer Center, Moffitt Cancer Center, Dana-Farber Cancer Institute, Cleveland Clinic, University of California, Los Angeles, Tennessee Oncology, Stanford University, Swedish Medical Center, Amsterdam University Medical Centers, University of Amsterdam, Centre Hospitalier Universitaire de Bordeaux, Universitätsklinikum Würzburg, Inserm, Centre Hospitalier Universitaire de Rennes, Université de Rennes, University of Miami, University of Rochester Medicine, University of Rochester
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4405038504